ArticleRenal failure2026
Urinary NGAL and trehalase predict end-stage kidney disease in ANCA-associated vasculitis: a prospective cohort study.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate prediction of renal outcomes in ANCA-associated vasculitis (AAV) is critical. This study evaluated the predictive value of urinary biomarkers for end-stage kidney disease (ESKD) progression.
methodsA prospective cohort of 88 AAV patients with renal involvement was followed for a median of 27 months. Urinary β-catenin, IL-18, trehalase, and NGAL were measured. Cox regression and ROC analyses assessed associations and predictive performance.
results65 patients (73.9%) progressed to ESKD. Urinary trehalase and NGAL were significantly elevated in the ESKD group and were independent predictors of ESKD in multivariable analysis (both
conclusionUrinary trehalase and NGAL are strong, noninvasive predictors of ESKD in AAV, and their combination enhances risk stratification, supporting potential clinical utility for personalized treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.